Environmental, Social and Governance
Since our founding, GBT’s business strategies, values and social purpose have been intentionally woven together, ensuring Environmental, Social and Governance (ESG) is always at the core of our business.
A letter from our CEO,
Ted W. Love, M.D.
Millions of people around the world live with sickle cell disease (SCD), an inherited blood disorder that is rare outside of the African continent, the Middle East and India. It primarily impacts people of color and carries a significant burden from a health, social and economic perspective. Those living with SCD have an elevated risk of stroke, organ damage and organ failure, and sadly, they die 30 years earlier, on average, than the general public.
The fundamental cause of SCD has been understood for decades, but therapeutic innovation and equitable access to care have lagged considerably as compared to other diseases. SCD affects particularly vulnerable groups in society that have historically faced difficulties in accessing healthcare, building trust with healthcare systems and navigating a traditionally discriminatory system, and the COVID-19 pandemic has only further exacerbated these vulnerable populations. The SCD community has been underserved for far too long, and Global Blood Therapeutics (GBT) is committed to righting this injustice.
Our employees – or GBTers – around the world use the power of science, empathy and community to advance our goal to transform the lives of people with SCD and other underserved orphan diseases. To get there, we must innovate and address the historical lack of understanding and attention these diseases have received from the healthcare system, government institutions and society.
Since our founding in 2011, we have spent more than $750 million on research and development for investigational agents that treat SCD. This led to our first approved medicine in 2019, Oxbryta® (voxelotor) tablets, and an innovative pipeline covering a diverse set of approaches to treating SCD.
Our Environmental, Social and Governance (ESG) strategy is aligned with the cultural values that have long guided our team and that are woven into GBT’s DNA as a company: innovation, inclusion, accountability and community.
Our approach to ESG has evolved over our history, and we are focusing on areas where we believe we will make the greatest difference and deliver long-term sustainable value for our business and society. As you’ll see in our inaugural ESG report, these areas are: improving access to affordable healthcare, to improve the lives of patients; investing in GBT employees and communities, to power our ability to deliver for patients; increasing our environmental sustainability, as health equity and environmental health are related; and upholding our ethics and values, which are the foundation of everything we do.
I’m proud that our first ESG report demonstrates our progress with these priorities and our commitment to advancing GBT’s ESG journey by thinking differently, setting more ambitious goals, and holding ourselves accountable through our governance and reporting practices.
We are at a pivotal moment in time for SCD patients. While new medicines are becoming available, significant gaps still remain in the care and health equality for the SCD community. Together, we’re advancing on both fronts to transform SCD patient lives and ensure a sustainable future built through Hope + Science + Community.
Ted W. Love, M.D.
GBT President & CEO
Our Four Key
ESG Focus Areas
Affordable Access to Treatment
We are advancing health equity to ensure communities of color have access to our medicines and affordable healthcare. We believe that addressing fundamental health equity issues and systemic barriers to care through therapeutic innovation is essential in order to help SCD patients optimize their care journey. Our bold vision to expand access to care includes what we believe to be the deepest pipeline in SCD.
Employees and Communities
We believe fostering a diverse values-driven culture that cultivates and develops talent reflective of the communities where we live and work and advances corporate citizenship is key to fostering innovation, increasing access and reducing disparities. Our team is passionate about our cultural values, which focus on innovation, inclusion, accountability and community.
We are committed to reducing our footprint to protect the environment and reduce health impacts from climate change. Much of our global patient population and caregiver base is located in underserved communities, often the hardest hit by climate and other environmental impacts.
Ethics and Values
As a values-centered culture, we engage all stakeholders and operate with the highest standards of integrity and transparency in our research, operations, sales and marketing, in line with our cultural values.